Medifast
Medifast's revenue fell 36.0% to $386 million in fiscal 2025. Its operating margin was −3.7%, down from 0.5% a year earlier. Free cash flow was $1 million, down 92.7%. It paid out $0 million in dividends and buybacks, 16% of free cash flow. The diluted share count rose 0.2%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
From fiscal 2016 to 2024, earnings per share fell 22.7% a year and net income 23.4% a year, while buybacks cut the share count by 8%. Medifast then lost money in fiscal 2025.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 110 | 88 | 149 | 166 | 166 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 1.8x | 1.6x | 2.4x | 3.3x | 4.7x |
| Quick ratio | 0.8x | 0.7x | 1.8x | 2.7x | 4.2x |
Cash flow
Projections
Project Medifast's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 3 insiders bought $1.7 million of Medifast shares on the open market, and 1 insider sold $226,300, all of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 29, 2026 | Daniel R ChardDirector | Sold plan | 9,544 | $11.73 | $111,951 | Form 4 |
| Sep 28, 2026 | Daniel R ChardDirector | Sold plan | 9,545 | $11.98 | $114,349 | Form 4 |
| Aug 26, 2026 | Parsa KiaiDirector | Bought | 43,150 | $12.26 | $529,019 | Form 4 |
| Aug 24, 2026 | Parsa KiaiDirector | Bought | 4,329 | $12.00 | $51,948 | Form 4 |
| Aug 20, 2026 | Parsa KiaiDirector | Bought | 43,150 | $11.60 | $500,540 | Form 4 |
| Aug 19, 2026 | Parsa KiaiDirector | Bought | 29,337 | $11.66 | $342,069 | Form 4 |
| May 11, 2026 | Scott SchlackmanDirector | Bought | 2,500 | $12.53 | $31,325 | Form 4 |
| May 8, 2026 | Scott SchlackmanDirector | Bought | 2,500 | $12.65 | $31,625 | Form 4 |
| Mar 20, 2026 | Daniel R ChardChairman & CEO, Director | Bought | 17,678 | $10.11 | $178,725 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −19.8% | −41.0% | −35.6% |
| Altman Z'' | 9.32 | 8.54 | 10.15 |
| Accruals ratio | −15.4% | −7.5% | −9.6% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Pass | Fail |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Fail | Fail | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Pass | Pass | Pass |
| Share count didn't rise | Pass | Fail | Fail |
| Gross margin rose | Pass | Pass | Fail |
| Revenue rose relative to assets | Fail | Fail | Fail |
| F-score | — | — | — |
Compare
Put Medifast side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Medifast | FY25 | −36.0% | −3.7% | 0.3% | — | — | — | |
| Black Rifle Coffee | FY25 | 1.7% | −6.2% | −3.4% | −18.9% | — | 4 | Compare |
| Beyond Meat | FY25 | −15.6% | −121.1% | −57.1% | −94.8% | — | 3 | Compare |
| DDC Enterprise | FY25 | 0.3% | −90.0% | −101.3% | −100.2% | — | — | Compare |
| Bridgford Foods | FY25 | 3.3% | −8.1% | −4.0% | −12.4% | — | 3 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 274 | 302 | 501 | 714 | 935 | 1,526 | 1,599 | 1,072 | 602 | 386 |
| Revenue growth | 0.7% | 9.8% | 66.1% | 42.5% | 31.0% | 63.2% | 4.8% | −32.9% | −43.8% | −36.0% |
| Gross profit | 206 | 228 | 380 | 537 | 698 | 1,128 | 1,140 | 776 | 445 | 275 |
| Research and development | 2 | 2 | 2 | 3 | 3 | 4 | 4 | 5 | 5 | 4 |
| Operating income | 27 | 40 | 69 | 91 | 134 | 216 | 185 | 126 | 3 | −14 |
| Net income | 18 | 28 | 56 | 78 | 103 | 164 | 144 | 99 | 2 | −19 |
| Diluted EPS (US$) | 1.49 | 2.29 | 4.62 | 6.43 | 8.68 | 13.89 | 12.73 | 9.10 | 0.19 | −1.70 |
| Diluted shares (millions) | 12 | 12 | 12 | 12 | 12 | 12 | 11 | 11 | 11 | 11 |
| Cash flow | ||||||||||
| Cash from operations | 25 | 43 | 61 | 84 | 145 | 94 | 195 | 148 | 24 | 7 |
| Capital expenditure | 3 | 3 | 5 | 10 | 6 | 34 | 17 | 6 | 8 | 6 |
| Free cash flow | 22 | 40 | 56 | 74 | 139 | 60 | 178 | 141 | 17 | 1 |
| Dividends paid | 12 | 15 | 23 | 35 | 53 | 64 | 72 | 73 | 1 | 0 |
| Share buybacks | 0 | 0 | 30 | 33 | 5 | 56 | 126 | 4 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 3 | 4 | 3 | 4 | 7 | 10 | 11 | 8 | 7 | 8 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 77 | 99 | 101 | 93 | 174 | 110 | 88 | 149 | 166 | 166 |
| Debt incl. finance leases | — | — | — | — | — | — | — | — | — | — |
| Total assets | 121 | 146 | 169 | 195 | 276 | 398 | 316 | 310 | 284 | 248 |
| Total liabilities | 25 | 37 | 60 | 90 | 119 | 196 | 161 | 108 | 74 | 49 |
| Shareholders' equity | 96 | 107 | 109 | 105 | 157 | 202 | 155 | 202 | 210 | 199 |
| Margins and ratios | ||||||||||
| Gross margin | 74.9% | 75.5% | 75.8% | 75.2% | 74.7% | 73.9% | 71.3% | 72.4% | 73.8% | 71.3% |
| Operating margin | 9.8% | 13.1% | 13.8% | 12.8% | 14.3% | 14.2% | 11.6% | 11.8% | 0.5% | −3.7% |
| Net margin | 6.5% | 9.2% | 11.1% | 10.9% | 11.0% | 10.8% | 9.0% | 9.3% | 0.3% | −4.8% |
| Free cash flow margin | 8.2% | 13.3% | 11.2% | 10.4% | 14.9% | 4.0% | 11.1% | 13.2% | 2.8% | 0.3% |
| Rule of 40 (growth + FCF margin) | 8.8% | 23.1% | 77.3% | 52.9% | 45.9% | 67.2% | 15.9% | −19.8% | −41.0% | −35.6% |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | 19.3% | 27.4% | 51.7% | 72.8% | 78.5% | 91.2% | 80.3% | 55.8% | 1.0% | −9.1% |
| Return on assets | 15.0% | 20.8% | 35.4% | 42.8% | 43.7% | 48.6% | 40.2% | 31.8% | 0.7% | −7.0% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |